Drugs / Hexakaprone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02362945 | Oct 2015 → Jan 2017 | — | Yariv yogev | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hexakaprone | “Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic” NCT02362945 ↗ |
| Known as | Transexamic acid | “Transexamic acid - Hexakapron is a potent antifibrinolytic, it prevents lysine adhesion to plasminogen molecules by blocking its binding site.” NCT02362945 ↗ |
| Action | Inhibit | “it prevents lysine adhesion to plasminogen molecules by blocking its binding site” NCT02362945 ↗ |
| Route | Intravenous | “Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus” NCT02362945 ↗ |